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Abstract
Background: Toxoplasma gondii is an obligate intracellular parasite which can infect almost all mammalian animals,
leading to toxoplasmosis. T. gondii rhoptry protein 38 (TgROP38) is an active rhoptry protein kinase which is
involved in the inhibitory effect on host cell transcription by down-regulating the MAPK signaling track.
Methods: TgROP38 gene was amplified and inserted into eukaryotic vector pVAX I and formed the DNA vaccine
pVAX-ROP38. Mice in the experimental group were intramuscularly immunized with pVAX-ROP38 and those injected
with pVAX I, PBS or nothing were treated as controls. After three injections at two week intervals, all mouse groups
were challenged intraperitoneally with 1000 tachyzoites of the virulent T. gondii RH strain (Type I, ToxoDB #10) and
10 cysts of the PRU strain (Type II, ToxoDB #1), respectively.
Results: Mice inoculated with pVAX-ROP38 vaccine had a higher level of IgG antibodies (P < 0.01) and T
lymphoproliferative response. The high ratio of IgG2a/IgG1 and the increasing levels of IFN-γ and IL-2 (P < 0.05) indicated
an activated Th1 cell-mediated immune responses. Furthermore, the CD4+ and CD8+ proportions in vaccinated mice were
also increased significantly compared with that in mice of the three control groups (P < 0.01). In the model of acute
infection, the average survival time of mice in the pVAX-ROP38 group (8.1 days ± 0.75) was no statistically different
compared to that in the PBS, pVAX I and blank control groups which died within 7 days. However, in the model of
chronic infection, the brain cyst reduction in the pVAX-ROP38 group reached 76.6%, compared to controls (P < 0.01).
Conclusions: The present study revealed that the pVAX-ROP38 vaccine could elicit strong humoral and cell immunity
response against chronic T. gondii infection in mice, resulting in the reduction of the brain cyst formation effectively,
which suggests that TgROP38 is a desirable vaccine candidate against chronic T. gondii infection.
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Background
The obligate intracellular protozoa parasite Toxoplasma
gondii can infect virtually all warm-blooded hosts includ-
ing wild mammals, birds, livestock, poultry and human
beings throughout the world, posing a significant public
health concern [1,2]. The symptoms of T. gondii infection
in humans ranged from asymptomatic in immunocompe-
tent individuals to devastating in immune-compromised
individuals and unprotected fetuses [2-4]. Epidemiologic
survey results showed that the high T. gondii prevalence
in many economic animals led to considerable economic
losses [5-7].
Several chemical drugs such as sulphadiazine, atova-
quone and pyrimethamine could only control T. gondii
acute infection with few adverse effects, but can not
eliminate chronic infection [2,8,9]. Using vaccines, as
the successful application in prevention of hepatitis B
(HBV) or Bacille Calmette-Guerin (BCG), is thus of high
* Correspondence: xingquanzhu1@hotmail.com
1State Key Laboratory of Veterinary Etiological Biology, Key Laboratory of
Veterinary Parasitology of Gansu Province, Lanzhou Veterinary Research
Institute, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province
730046, P. R. China
2College of Animal Science and Technology, Anhui Agricultural University,
Hefei, Anhui Province 230036, P. R. China
© 2014 Xu et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Xu et al. BMC Infectious Diseases 2014, 14:525
http://www.biomedcentral.com/1471-2334/14/525
priority [10], but so far only one attenuated-live T. gondii
vaccine was available for veterinary uses, and no vaccine is
available for defending against T. gondii infection in
humans [11,12]. DNA vaccines were considered to be
more efficient and safer than live and attenuated-live
vaccines, as they were able to elicit long-lasting humoral
and cell-mediated immune responses, and significant
progress has been made in the identification of candidate
antigens against T. gondii in the last several years [12,13].
Rhoptry proteins (ROPs) were shown to exist on
the parasitophorous vacuole membrane and were also
identified to be the virulence factors participating in T.
gondii invasion [14,15]. Due to their key biological roles,
T. gondii rhoptry proteins 5, 13, 16 and 18 (TgROP5,
TgROP13, TgROP16 and TgROP18) have been proven as
potential vaccine candidates [16-19]. T. gondii rhoptry
protein 38 (TgROP38) is predicted to be an active rhop-
try protein kinase (ROPK) that could have an inhibitory
effect on host cell transcription by down-regulating the
MAPK signaling track [20-22]. TgROP38 is observed
inside rhoptries and is dramatically expressed among T.
gondii genotypes (up 64 times in VEG strain, up 8 times
in ME49 strain compared with the RH strain) [20,21].
Furthermore, the low sequence variation in TgROP38
gene among different T. gondii strains implied that
TgROP38 may represent a potential vaccine candidate
against T. gondii infection [23].
The objectives of the present study were to examine
the immunogenicity of the recombinant eukaryotic
expression plasmid pVAX-ROP38 and to evaluate the
acquired immuno-efficacy of this DNA vaccine against
challenge infection with highly virulent RH strain (Type I,
ToxoDB #10) and less virulent PRU strain (Type II,
ToxoDB #1) of T. gondii in a mouse model.
Methods
Mice and parasites
Specific-pathogen-free (SPF) grade female Kunming mice
aged six to eight weeks old were purchased from Lanzhou
University Laboratory Animal Center (Lanzhou, Gansu
Province, China). All mice were fed with basal diet and
tap water ad libitum in strict accordance with Good
Animal Practice requirements of the Animal Ethics
Procedures and Guidelines of the People’s Republic of
China, and the study was approved by the Animal Ethics
Committee of Lanzhou Veterinary Research Institute,
Chinese Academy of Agricultural Sciences (Approval No.
LVRIAEC2012-011).
The PRU strain was kept in Kunming mice by oral
passage of 10 brain cysts. Tachyzoites of the RH strain
were preserved in liquid nitrogen in the Department of
Parasitology, Lanzhou Veterinary Research Institute,
Chinese Academy of Agricultural Sciences (Lanzhou,
Gansu Province, China), and harvested from the peritoneal
fluids through serial intraperitoneal passage in Kunming
mice. The tachyzoites were also used for preparing soluble
tachyzoite antigens (STAg) by ultrasonication after washing
by sterile phosphate-buffered saline (PBS). The lysate was
then centrifuged at 10, 000 × g for 15 min and the super-
natant was kept at −80°C until further use.
Construction of the eukaryotic expression plasmids
The complete ROP38 gene sequence of ME49 strain in
ToxoDB database (TGME49_242110) was used to design
specific primers ROP38U1 (5′-CGGGGTACCATGAAA
AATACTCTGTTGTCA-3′) and ROP38D1 (5′- TGCT
CTAGATCAAAATTGATGCGTTCTTAT-3′), in which
Kpn I and Xba I recognition sites were introduced in
both primers and underlined. The ORF of TgROP38
gene was amplified by PCR using genomic DNA (gDNA)
from T. gondii RH strain as template. The PCR product
was purified by using TIANquick Midi Purification Kit
(TIANGEN, Beijing, China). The purified PCR product
and vector pVAX I (Invitrogen, Carlsbad, California,
USA) were then cleaved by Kpn I and Xba I. The
TgROP38 fragment was then inserted into vector pVAX
I using T4 ligase enzyme, and formed pVAX-ROP38.
The concentration of the recombinant plasmids was
determined using a spectrophotometer at OD260 and
OD280. The plasmids were diluted with PBS to a final
concentration of 1 μg/μl and stored at −20°C.
Expression of pVAX-ROP38 in vitro
The recombinant plasmid pVAX-ROP38 and empty
vector pVAX I were transfected into HEK 293 cells, re-
spectively, using lipofectamine 2000 reagent (Invitrogen)
according to the manufacturer’s instructions. Indirect
immunofluorescence assay (IFA) was used to detect the
expression of pVAX-ROP38 at 48 hours as described
previously [24].
Construction of the prokaryotic expression plasmids
To amplify TgROP38 gene and ligate to the prokaryotic
expression vector pET-30a(+), Kpn I and BamH I recog-
nition sites were introduced in the primers. Then both
PCR products and the pET-30a(+) were digested by Kpn
I and BamH I, respectively. The extracted TgROP38 gene
fragment was linked into purified linear vector pET-30a
(+) by T4 DNA ligase (TaKaRa, Dalian, Liaoning Province,
China), formed the pET-ROP38 recombinant plasmid.
Expression of TgROP38 protein in E. coli BL21 (DE3)
The obtained recombination plasmids were transferred
into E. coli BL21 (DE3) competence cell and grown in
Luria Bertani (LB) with kanamycin (25 μg/ml). The re-
combinant TgROP38 (rTgROP38) protein was expressed
under the condition of 1.0 mM IPTG (Sangon, Shanghai,
China) and shaking for 8 hours at 37°C. Then the protein
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was purified using Ni-NTA His bind resin (Novagen,
Shanghai, China) according to the manufacturer’s in-
structions. The purified protein was examined by 10%
sodium dodecyl sulfare polyacrylamide gel electrophor-
esis (SDS-PAGE), and then diluted by sterile PBS to a
final concentration of 10 μg/ml and stored at −80°C.
Immunization and challenge
Three groups of mice (28 per group) were injected
intramuscularly with 100 μl diluted pVAX-ROP38 DNA
vaccine, PBS or empty pVAX I plasmid, respectively.
Another group of 28 mice were kept as blank control
without injection. The last three groups were served as
control groups. Mice in the pVAX-ROP38 DNA vaccine,
PBS and pVAX I groups were vaccinated three times
with a two-week interval. The blood of mice in each
group was collected from mouse tail vein before each
immunization and the sera were separated and stored at
−20°C for detection of specific antibodies.
Two weeks after the last immunization, 10 mice in
each group were challenged intraperitoneally with 1000
tachyzoites of the virulent T. gondii RH strain, and other
6 mice were inoculated with 10 cysts of the attenuated
virulent PRU strain orally. Mice injected with RH strain
were observed twice a day for mortality until a fatal
outcome for all animals. The brain cysts were determined
one month after the challenge infection. Each brain was
homogenized in 2 ml PBS, and the mean number of cysts
per brain was calculated.
Immunoblotting analysis of the recombinant protein
The purified rTgROP38 protein was identified by western
blotting after 10% SDS-PAGE. The protein was semi-dry
transferred onto nitrocellulose (NC) membranes (Pall,
New York, USA) at 15 V for 10 min. Then nonspecific
binding sites were blocked with 5% bovine serum albumin
(BSA) in PBST (PBS plus 0.05% Tween-20) for 1 h at
room temperature (RT). The NC membranes were then
incubated for 1 h at RT with the sera of immunized mice
on week 6 (diluted in 1:200) and non- immunized sera on
week 0 as negative control, respectively. After being
washed 3 times with PBST, the membranes were incu-
bated with diluted secondary antibody (goat anti-
mouse IgG-HRP, Sigma, St. Louis, Missouri, USA; 1:
5000) for 1 h at RT. Proteins were visualized with 4-chloro-
1-naphthol (4-CN; Sangon) according to the manufacturer’
instruction.
Evaluation of humoral response to pVAX-ROP38
Levels of antigen-specific IgG, IgG1 and IgG2a anti-
bodies in mouse serum samples were detected by
ELISA using SBA Clonotyping System-HRP Kit (Southern
Biotech Co., LTD, Birmingham, Alabama, USA). A total
of 100 μl rTgROP38 (10 μg/ml) was coated on 96-well
microtiter plates at 4°C overnight. Mouse serum sam-
ples were added to the wells and incubated at RT for 1 h
with gentle shaking. Then each well was incubated with
100 μl of horseradish-peroxidase (HRP) conjugated
anti-mouse IgG diluted at 1:250, anti-mouse IgG1 or
IgG2a (1: 500) as secondary antibodies for 1 h with gen-
tle shaking. After adding 3, 3′, 5, 5′-Tetramethylbenzi-
dine substrate solution (TMB) (5% TMB; 0.03% H2O2)
for 15 min, the reaction was terminated by adding 2 M
H2SO4 stopping solution and the absorbance was mea-
sured at 450 nm. All measurements were performed in
triplicate.
Splenocytes proliferation analysis by MTS
Two weeks after the last immunization, three mice of
each group were euthanized and their spleens were
removed aseptically. A single-cell suspension of sple-
nocytes was prepared as described previously [17].
Cells were then covered in 96-well microtiter plates
(Costar, Washington DC, USA) at a density of 5 × 105
cells per well, and cultured with Concanavalin A (ConA;
5 μg/ml; Sigma) or STAg (10 μg/ml) or medium alone,
respectively. After incubation at 37°C in a 5% CO2 in-
cubator, the proliferative activity was measured by
MTS method (Promega, Madison, Wisconsin, USA)
four days later. All assays were performed in triplicate.
The stimulation index (SI) was calculated by using the
formula (OD570STAg/OD570M): (OD570ConA/OD570M).
Identification of CD4+ and CD8+ T cells by flow cytometry
analysis
The percentage of T cell subclasses including CD4+ and
CD8+ in spleen were determined by flow cytomety
analysis. With staining by phycoerythrin (PE)-labeled
anti-mouse CD3 (eBioscience, San Diego, California,
USA), allophycocyanin (APC)-labeled anti-mouse CD4
(eBioscience) and fluorescein isothiocyanate (FITC)-
labeled anti-mouse CD8 (eBioscience) antibodies, the
single-cell suspension splenocytes were washed by PBS,
the cells were then fixed with FACScan buffer (PBS
containing 1% FCS and 0.1% Sodium azide) and 2%
paraformaldehyde. All samples were analyzed using
SYSTEM II software through FACScan flow cytometer
(BD Biosciences, San Jose, California, USA).
Cytokine assays
The splenocyte suspension from each group was co-
cultured with STAg in a 5% CO2 incubator at 37°C, and
the supernatants were collected at 24 h, 24 h, 72 h and
96 h for determining the level of IL-2, IL-4, IL-10 and
IFN-γ, respectively. All of the samples were examined
in triplicate using commercial ELISA kits following
the manufacturer’s instructions (BioLegend, San Diego,
California, USA).
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Statistical analysis
Data are presented as the mean ± SD. All statistical
analyses including antibody responses, splenocytes
proliferation assays, flow cytometric assays, cytokine
assays and survival time were carried out by the two-way
AVONA test, GraphPad Prism5.0® (GraphPad Software,
Inc., San Diego, California, USA). P value of less than 0.05
or 0.01 was considered significantly different or highly
significant different, respectively.
Results
Eukaryotic and prokaryotic expression of TgROP38
protein
Specific green fluorescence in the HEK 293 cells trans-
fected with the recombinant plasmid was observed, but
not in the negative controls transfected with the same
amount of empty pVAX I (Figure 1), showing that
recombinant TgROP38 protein was expressed in HEK
293 successfully.
The recombinant plasmid pET-ROP38 was expressed
in E. coli BL21 (DE3) and examined by SDS-PAGE and
western-blot. The results showed that the rTgROP38
protein was approximately 66 kDa, which was consistent
to the expected molecular weight, and was recognized
by anti-ROP38 antibody (Figure 2).
Antibody detection
The levels of specific antibodies IgG, IgG1 and IgG2a
were detected by ELISA. Compared with the three con-
trol groups, a statistically significantly higher level of
IgG antibody was detected in the sera of mice immu-
nized with pVAX-ROP38 (P < 0.01), and the OD values
of IgG were continuously increased with successive
DNA immunization. There were no statistically signifi-
cantly differences in IgG levels among the three control
groups (Figure 3).
The levels of IgG1 and IgG2a in the experimental
group (immunized with TgROP38) were also the high-
est in comparison with that of the three control groups
(P < 0.01) (Figure 4). The type of immune response
induced by the pVAX-ROP38 was evaluated by the ratio
of IgG1/IgG2a. The results showed that a significantly
higher IgG2a value than IgG1 from the sera collected on
week 6 was detected in mice immunized with pVAX-
ROP38, while no significantly differences were observed
in the controls (Figure 4), demonstrating that a Th1-type
cell immune response was elicited by immunization with
pVAX-ROP38.
Splenocyte proliferation
Proliferation SI measured at OD570nm in mice vaccinated
with pVAX-ROP38 (0.90 ± 0.02) was similar to that im-
munized with PBS (0.91 ± 0.01), pVAX I (0.89 ± 0.07)
and blank control (0.97 ± 0.01) (P > 0.05) (Table 1).
Evaluation of the percentages of CD4+ and CD8+ of T
lymphocytes
After third immunization, the percentage of CD3+ CD4+
CD8− and CD3+ CD8+ CD4− T lymphocytes in the
Figure 1 The indirect immunofluorescence assay (IFA) analysis of Toxoplasma gondii rhoptry protein 38 (TgROP38). (A) HEK 293 cells
were transfected with pVAX-ROP38; (B) empty vector pVAX I.
Figure 2 Identification of recombinant rhoptry protein 38
(rTgROP38) of Toxoplasma gondii by SDS-PAGE and Western-blot.
M: unstained protein marker; 1: Fusion protein TgROP38 expressed by
pET-ROP38 recombinant plasmid; 2: Purified fusion protein TgROP38; 3:
Western-blot analysis of fusion protein TgROP38.
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pVAX-ROP38 group were significantly higher than
those in the control groups, respectively (P < 0.01)
(Table 2). But there were no significantly differences in
the ratio of CD8+/CD4+ between mice immunized with
pVAX-ROP38 and in controls (P > 0.05).
Cytokine production
The cytokines produced by spleen cells from the four
groups of mice were evaluated by ELISA. The results
showed a significantly high level of both IFN-γ and IL-2
in the pVAX-ROP38 group compared with that in the
three control groups (P < 0.05). However, the level of
IL-10 from spleen cells of the mice immunized with
pVAX-ROP38 was significantly decreased compared to
those in control groups (P < 0.01) (Table 3).
Protection against T. gondii challenge
The survival rate of mice after acute T. gondii infection
in the four groups is shown in Figure 5. After challenge
infection intraperitoneally with a fatal dose of tachyzoites
of the virulent T. gondii RH strain, the average survival
time of mice in the pVAX-ROP38 group was slightly
longer than that of the three control groups, but the
difference was not statistically significant (P > 0.05)
(Figure 5). The mice received PBS and pVAX I showed
similar survival time compared to the blank control
group (Figure 5).
The number of brain cysts in mice of the four groups
is showed in Table 4. The number of brain cysts in mice
from the experimental group (immunized with pVAX-
ROP38) was significantly decreased (76.6%) compared to
that of the three control groups (P <0.01).
Discussion
T. gondii is an important zoonotic Apicomplexan para-
site, but no drugs could eliminate the pathogen from
the host effectively. In recent studies, DNA vaccines
have shown the potential to defend against T. gondii
infection in view of their abilities to induce long-term
humoral and cellular immune responses in animal
models. Many rhoptry proteins (ROP5, ROP13, ROP16
and ROP18) [16-19] are identified to be potential
Figure 3 Detection of specific IgG antibodies in mice after immunization with Toxoplasma gondii rhoptry protein 38 (TgROP38). Serum
samples were detected at 2 weeks interval by ELISA. Data are presented as the mean ± SD (n = 3). *** represents highly significantly differences
(P < 0.01) compared with the control groups.
Figure 4 Specific IgG1 and IgG2a pattern upon immunization with pVAX-ROP38. Data are presented as the mean ± SD (n = 3). *** represents
highly significantly differences (P < 0.01) compared with the control groups.
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candidates for development of T. gondii DNA vaccines.
TgROP38, a new member of the rhoptry protein family,
was firstly identified by the phylogenomic approach
and was found to regulate the expression of host tran-
scription factors, signaling pathways and cell prolifera-
tion, and apoptosis that sum up about 1200 host genes
[21]. These key biological roles of TgROP38 in T.
gondii infection of the host have stimulated us to
evaluate whether TgROP38 could elicit effective im-
mune responses against infection with T. gondii in the
mice model. Therefore, we constructed the recombin-
ant plasmid pVAX-ROP38 and evaluated its vaccinal
potentiality and the acquired immune responses it
elicited.
Immunization of mice with pVAX-ROP38 induced
significantly reduction of brain cysts (76.6%) in the vac-
cinated mice compared to the controls, and this efficacy
is better than other single gene vaccines including
TgIF2α (44.1%) [25] and TgCDPK3 (50%) [24]. However,
immunization of mice with pVAX-ROP38 had virtually
no effects on the prolonged survival time of mice in the
pVAX-ROP38 group following challenge infection with
the highly virulent RH strain. This is likely due to the
low expression of TgROP38 in tachyzoites, thus the
relatively low responsivity to tachyzoited TgROP38
induced by immunization with pVAX-ROP38 failed to
prevent T. gondii RH strain invasion in the mice model.
However, the expression of TgROP38 gene is up-regulated
in the bradyzoite stage [20,21], and it is speculated that
TgROP38 participates in the tissue cyst formation, thus
contributes to the significant decrease of brain cysts
in pVAX-ROP38 vaccinated mice after challenge with
PRU strain.
The specific antibodies against T. gondii can inhibit
the parasite to attach to the host cell receptors, and can
promote macrophages to kill intracellular parasites, which
seem to be important in controlling T. gondii infection
and preventing reactivation [26]. In the present study,
the high level of specific IgG antibody against TgROP38
was induced in the experimental group (pVAX-ROP38
vaccinated mice) compared with three control groups
(P < 0.01). Further analyses of the ratio of IgG1/ IgG2a
revealed a higher level of IgG2a, indicating that pVAX-
ROP38 could elicit the Th1-biased immune response,
which is considered to play a critical role in the protective
immunity against T. gondii [27,28].
Among the subclasses of T lymphocytes, CD4+ and
CD8+ T lymphocytes play an important role in host re-
sistant to T. gondii infection. The CD3+ CD4+ CD8− is
the surface marker of T helper (TH) cells that can par-
ticipate in the adaptive immune responses, while CD3+
CD8+ CD4− is expressed on cytotoxic T cells (CTLs)
which is classified as a pre-defined cytotoxic role within
the immune system [29]. Also, it has been demonstrated
that CD8+ T cells are pivotal for long-term protection in
murine models of chronic toxoplasmosis [30].
Table 3 Cytokine production of splenocytes induced by
STAg
Groups Cytokine production
IFN-γ IL-2 IL-4 IL-10
Blank control 47.3 ± 16.6 12.7 ± 8.0 11.6 ± 9.5 477.3 ± 87.5
pVAX I 34.9 ± 11.2 12.4 ± 11.8 12.1 ± 3.4 322.5 ± 179.2
PBS 36.4 ± 4.8 11.3 ± 6.0 13.3 ± 1.8 356.1 ± 175.3
pVAX-ROP38 575.2 ± 123.0*** 195.3 ± 28.4* < 5 48.7 ± 24.3***
STAg soluble tachyzoite antigens.
Data are presented as the mean ± SD (n = 3).
*represents statistically significant difference (P < 0.05).
***represents statistically highly significant difference (P < 0.01).
Figure 5 Survival curve of mice after challenge infection with
Toxoplasma gondii RH strain. Mice were challenged with 1000
tachyozoites of the RH strain intraperitoneally two weeks after the
third immunization.
Table 1 Proliferation SI of mice in each group
Groups SI
Blank control 0.97 ± 0.01
pVAX I 0.89 ± 0.07
PBS 0.91 ± 0.01
pVAX-ROP38 0.90 ± 0.02
Data are presented as the mean ± SD (n = 3). The stimulation index (SI) was
calculated by using the formula (OD570STAg/OD570M): (OD570ConA/OD570M).
Table 2 CD4+ and CD8+ of T lymphocytic subclasses
Groups CD3+ CD4+ CD8− CD3+ CD8+ CD4− Ratio
Blank control 15.3 ± 1.9 5.0 ± 0.4 3.0 ± 0.2
pVAX I 14.2 ± 1.9 6.5 ± 1.2 2.2 ± 0.5
PBS 13.7 ± 2.4 6.4 ± 1.3 2.2 ± 0.2
pVAX-ROP38 29.3 ± 1.1*** 13.6 ± 0.8*** 2.2 ± 0.1
Samples were detected by flow cytometric assays, and data are presented as
the mean ± SD (n = 3).
***represents statistically highly significant difference (P < 0.01).
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In this study, both CD3+ CD4+ CD8− and CD3+ CD8+
CD4−were significantly increased in the vaccinated mice
(P < 0.01) compared to the controls with a slightly higher
ratio of CD3+ CD8+ CD4−/CD3+ CD4+ CD8−, indicating
that DNA immunization with pVAX-ROP38 could elicit
a synergistic effect on CD4+ helper T-lymphocytes and
CD8+ and cytotoxic T-lymphocytes. CD8+ T cells can
control T. gondii infection through the production of
inflammatory cytokines. The increased levels of IFN-γ in
the mice immunized with pVAX-ROP38 contribute to
induce protective immunity against infection with T.
gondii PRU strain.
IFN-γ could differentiate naive CD4+ T cells (Th0 cells)
into Th1 cells, while suppress Th2 cell differentiation
[31,32]. The cytokine is secreted by TH cells, CTL cells
or NK cells and has antiviral, immunoregulatory and
anti-tumor functions [33]. When antigens bind to the T
cell receptors (TCRs), IL-2 is stimulated to secrete espe-
cially in adaptive immunity, thus IL-2 regulates the
growth, differentiation and survival of antigen-specific
CD4+ T cells and CD8+ T cells and participates in the
development of immunological memory [34,35]. The
present study observed significantly increased levels of
IFN-γ and IL-2 in pVAX-ROP38 immunized mice. IL-4
can up-regulate MHC class II production [36], and IL-10
inhibits B and T lymphocytes proliferation and suppresses
human macrophages activity in vivo [37-39]. The sharply
increased levels of IFN-γ and IL-2 and the decreased
levels of IL-4 and IL-10 cytokines in mice immunized with
pVAX-ROP38 demonstrated that a strongly Th1-type im-
mune response was elicited.
Conclusion
In summary, this study revealed that DNA vaccine
pVAX-ROP38 encoding TgROP38 can trigger strong
humoral and cellular immune responses, and can protect
against the formation of T. gondii brain cysts. TgROP38
warrants further studies as a potential vaccine candidate
against chronic T. gondii infection.
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